David A. Sallman

9.1k total citations
293 papers, 3.8k citations indexed

About

David A. Sallman is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, David A. Sallman has authored 293 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 234 papers in Hematology, 122 papers in Genetics and 67 papers in Molecular Biology. Recurrent topics in David A. Sallman's work include Acute Myeloid Leukemia Research (218 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (82 papers) and Chronic Myeloid Leukemia Treatments (49 papers). David A. Sallman is often cited by papers focused on Acute Myeloid Leukemia Research (218 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (82 papers) and Chronic Myeloid Leukemia Treatments (49 papers). David A. Sallman collaborates with scholars based in United States, United Kingdom and France. David A. Sallman's co-authors include Alan F. List, Rami S. Komrokji, Eric Padron, Jeffrey E. Lancet, Kendra Sweet, Thomas Cluzeau, Kathy L. McGraw, Anthony M. Hunter, Chetasi Talati and Ashley A. Basiorka and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

David A. Sallman

262 papers receiving 3.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Sallman United States	31	2.6k	1.6k	1.0k	992	869	293	3.8k
Thomas Prébet France	32	2.9k 1.1×	2.0k 1.2×	1.0k 1.0×	735 0.7×	596 0.7×	171	4.2k
Felicitas Thol Germany	33	2.7k 1.1×	2.1k 1.3×	1.1k 1.1×	464 0.5×	524 0.6×	125	4.0k
Brenda Chyla United States	28	2.9k 1.2×	2.5k 1.6×	1.5k 1.5×	968 1.0×	467 0.5×	84	4.8k
Sergej Konoplev United States	35	2.2k 0.9×	1.4k 0.8×	1.2k 1.2×	1.4k 1.4×	1.1k 1.2×	154	4.6k
Brian A. Jonas United States	26	2.5k 1.0×	1.9k 1.1×	691 0.7×	698 0.7×	285 0.3×	122	3.5k
John C. Byrd United States	19	1.7k 0.7×	1.5k 0.9×	1.4k 1.3×	720 0.7×	540 0.6×	81	3.7k
Yaping Shou United States	25	1.8k 0.7×	1.1k 0.7×	1.5k 1.5×	686 0.7×	303 0.3×	68	3.1k
Sören Lehmann Sweden	27	1.2k 0.5×	1.2k 0.7×	507 0.5×	667 0.7×	243 0.3×	77	2.3k
Claudia D. Baldus Germany	36	3.2k 1.2×	2.3k 1.4×	1.0k 1.0×	487 0.5×	332 0.4×	124	4.6k
Andreas Burchert Germany	27	1.3k 0.5×	792 0.5×	735 0.7×	641 0.6×	521 0.6×	93	2.4k

Countries citing papers authored by David A. Sallman

Since Specialization

Citations

This map shows the geographic impact of David A. Sallman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Sallman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Sallman more than expected).

Fields of papers citing papers by David A. Sallman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Sallman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Sallman. The network helps show where David A. Sallman may publish in the future.

Co-authorship network of co-authors of David A. Sallman

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Sallman. A scholar is included among the top collaborators of David A. Sallman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Sallman. David A. Sallman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jain, Akriti, Somedeb Ball, Onyee Chan, et al.. (2024). Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML. Annals of Hematology. 103(6). 1941–1945. 5 indexed citations

Xie, Zhuoer, Ling Zhang, Peter Papenhausen, et al.. (2024). Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm. SHILAP Revista de lepidopterología. 2(2). 100062–100062.

Lancet, Jeffrey E., Rami S. Komrokji, Javier Pinilla‐Ibarz, et al.. (2024). Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting. Blood. 144(Supplement 1). 2820–2820.

Komrokji, Rami S., Najla H. Al Ali, Zhuoer Xie, et al.. (2024). IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD). Blood. 144(Supplement 1). 3228–3228.

Kroger, Benjamin, Roni Tamari, Carmelo Gurnari, et al.. (2024). Prediction of Post-Transplant Relapse of the Myelodysplastic Syndromes Via Evaluation of Stem Cells. Blood. 144(Supplement 1). 777–777.

Zahra, Fatima Tuz, Onyee Chan, Jeffrey E. Lancet, et al.. (2024). Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience. Blood. 144(Supplement 1). 2415–2415. 1 indexed citations

Daver, Naval, Pau Montesinos, Jessica K. Altman, et al.. (2024). A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.. Journal of Clinical Oncology. 42(16_suppl). TPS6585–TPS6585. 1 indexed citations

Daver, Naval, Abhishek Maiti, David A. Sallman, et al.. (2024). A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).. Journal of Clinical Oncology. 42(16_suppl). TPS6586–TPS6586. 5 indexed citations

Komrokji, Rami S., Luis E. Aguirre, Najla H. Al Ali, et al.. (2023). Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes. Blood Advances. 7(14). 3677–3679. 7 indexed citations

10.

Rollison, Dana E., Brian D. Gonzalez, Kea Turner, et al.. (2023). Examining disparities in large‐scale patient‐reported data capture using digital tools among cancer patients at clinical intake. Cancer Medicine. 12(18). 19033–19046. 7 indexed citations

11.

Ferrall‐Fairbanks, Meghan C., Brian Johnson, Christopher T. Letson, et al.. (2022). Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes. Blood Cancer Discovery. 3(6). 536–553. 9 indexed citations

12.

Daver, Naval, Abhishek Maiti, Tapan M. Kadia, et al.. (2022). TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discovery. 12(11). 2516–2529. 83 indexed citations

13.

Aguirre, Luis E., Akriti Jain, Somedeb Ball, et al.. (2021). Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Blood. 138(Supplement 1). 1494–1494. 7 indexed citations

14.

Sallman, David A., Hany Elmariah, Kendra Sweet, et al.. (2021). Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes. Blood. 138(Supplement 1). 825–825. 21 indexed citations

15.

Komrokji, Rami S., Najla Al Ali, Onyee Chan, et al.. (2021). Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leukemia & lymphoma. 63(1). 199–204. 2 indexed citations

16.

Talati, Chetasi, Aaron D. Goldberg, Amanda Przespolewski, et al.. (2020). Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leukemia Research. 93. 106367–106367. 13 indexed citations

17.

Badar, Talha, Anikó Szabó, David A. Sallman, et al.. (2020). Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leukemia & lymphoma. 61(6). 1418–1427. 14 indexed citations

18.

Sallman, David A.. (2020). The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results. 26 indexed citations

19.

Sweet, Kendra, Rami S. Komrokji, Eric Padron, et al.. (2019). Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Clinical Cancer Research. 26(1). 54–60. 22 indexed citations

20.

Goldberg, Aaron D., Chetasi Talati, Pinkal Desai, et al.. (2018). TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia. Blood. 132(Supplement 1). 1433–1433. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact